Meta-analyses: Aspirin’s utility in chronic kidney disease isn’t clear

An increase in the risk of bleeding may nullify the benefits of antiplatelet therapy in patients with chronic kidney disease (CKD), according to a pair of meta-analyses.

The evidence from clinical trials included in the meta-analyses is of low quality, the authors reported, with numerous limitations. “Bleeding hazards and lack of clear efficacy need to be acknowledged when patients with CKD are being counseled about acute or long-term antiplatelet therapy,” the authors of the analysis concluded.

Key Point: Aspirin’s benefit in chronic kidney disease is uncertain given the low quality of evidence available. More studies are needed to guide patient recommendations in this area.

The prevalence of chronic renal failure in India is approximately 0.8%, with diabetes the most frequent cause, followed by hypertension (Nephrol Dial Transplant. 2006;21:232-233).

The researchers first assessed the effect of antiplatelet therapy using data from 9 clinical trials that...

Log in or register for free to continue reading
Register Now For Free Already Registered? Log In
This entry was posted in Cardiovascular Disease, Diabetes, Nephrology, Pharmacology, Primary Care and tagged , , , , , , , , . Volume: .

Post a Comment

You must be logged in to post a comment.